Astria Therapeutics Inc. has announced final positive results from the ALPHA-STAR Phase 1b/2 clinical trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in patients with hereditary angioedema $(HAE)$. The study, which enrolled 29 patients across 20 sites in six countries, demonstrated robust reduction in HAE attack rates and a favorable safety and tolerability profile. Both every three-month (Q3M) and every six-month (Q6M) dosing regimens were supported by the data. Clinically meaningful improvements in patient-reported quality of life were observed at six months. No serious treatment-emergent adverse events were reported. Topline results from the ongoing Phase 3 ALPHA-ORBIT trial are expected in early 2027.